Cyclosporine A in treatment of dry eye disease
Article Sidebar
Main Article Content
Abstract
Aim: Review of the current literature on the efficacy of cyclosporine A in the treatment of chronic dry eye syndrome.
Methods: The PubMed data base was reviewed, using the following key words: cyclosporine A, dry eye syndrome, tear film, inflammation. Additional conditions taken into consideration included: original publications, works published over the past 5 years, papers in English, studies involving human subjects. 9 original papers discussing chronic use of cyclosporine A were selected.
Results: 9 original papers on the efficacy of cyclosporine A treatment were selected for analysis. The prevailing regimen was twice daily administration of the drug in patients with dry eye syndrome. Studies demonstrated reduced local symptoms as well as a reduction in the amount of other topical drugs used, including glucocorticosteroids and artificial tears. A low rate of adverse events was reported, including painful administration and irritation of the eye.
Conclusions: Cyclosporine A is an effective drug that reduces local symptoms of the dry eye syndrome, with a small number of local and systemic adverse events.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Design and conduct of clinical trials: report of the Clinical Trials Subcommittee of the International Dry Eye WorkShop. Ocul Surf. 2007; 5: 153-62.
3. Straub M, Bron A, Muselier-Mathieu A et al. Long-term outcome after topical ciclosporin in severe dry eye disease with a 10-year follow-up. Br J Ophthalmol. 2016; 100(11): 1547-50.
4. Toker E, Asfuroğlu E. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy. Cornea. 2010; 29: 133-40.
5. Pisella PJ, Labetoulle M, Doan S et al. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018; 12: 289-99.
6. Leonardi A, Van Setten G, Amrane M et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016; 26(4): 287-96.
7. Baudouin C, de la Maza M, Amrane M et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017; 27(6): 678-85.
8. Iaccheri B, Torroni G, Cagini C et al. Corneal confocal scanning laser microscopy in patients with dry eye disease treated with topical cyclosporine. Eye (Lond). 2017; 31(5): 788-94.
9. Pérez-Rico C, Germain F, Castro-Rebollo M et al. Effect of topical 0.05% cyclosporine A on corneal endothelium in patients with dry eye disease. Int J Ophthalmol. 2013; 6(4): 471-4.
10. Devecı H, Kobak S. The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s syndrome. Int Ophthalmol. 2014; 34(5): 1043-8.
11. Chung YW, Oh TH, Chung SK. The effect of topical cyclosporine 0.05% on dry eye after cataract surgery. Korean J Ophthalmol. 2013; 27(3): 167-71.
12. Lee JH, Song IS, Kim KL et al. Effectiveness and Optical Quality of Topical 3.0% Diquafosol versus 0.05% Cyclosporine A in Dry Eye Patients following Cataract Surgery. J Ophthalmol. 2016; 2016: 8150757.
13. Gire AI, Karakus S, Ingrodi SM et al. Frequent Dosing of Topical Cyclosporine A for Severe Ocular Surface Disease. J Ocul Pharmacol Ther. 2016; 32(3): 150-4.
14. Schultz C. Safety and Efficacy of Cyclosporine in the Treatment of Chronic Dry Eye. Ophthalmol Eye Dis. 2014; 6: 37-42.
15. Sall K, Stevenson OD, Mundorf TK et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000; 107: 631-6.
16. Siak J, Chee SP. Cytomegalovirus Anterior Uveitis Following Topical Cyclosporine A. Ocul Immunol Inflamm. 2018; 26(1): 90-3.
17. Hermans K, Van Den Plas, Schreurs E et al. Cytotoxicity and anti-inflammatory activity of cyclosporine A loaded PLGA nanoparticles for ocular use. Pharmazie. 2014; 69(1): 32-7.